Literature DB >> 24121473

[Systemic therapy of metastatic bladder cancer.]

M Retz1, S C Schmid, M W Kramer, A S Merseburger.   

Abstract

This review focuses on current options in the medical therapy of metastasized urothelial carcinoma of the bladder. Standard treatments as well as new, recently published therapeutic approaches are evaluated and discussed.

Entities:  

Year:  2013        PMID： 24121473     DOI： 10.1007/s00120-013-3250-1

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  25 in total

Review 1.  Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

Authors:  Guru Sonpavde; Cora N Sternberg; Jonathan E Rosenberg; Noah M Hahn; Matthew D Galsky; Nicholas J Vogelzang
Journal:  Lancet Oncol       Date:  2010-05-25       Impact factor: 41.316

2.  Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Authors:  E Seront; S Rottey; B Sautois; J Kerger; L A D'Hondt; V Verschaeve; J-L Canon; C Dopchie; J M Vandenbulcke; N Whenham; J C Goeminne; M Clausse; D Verhoeven; P Glorieux; S Branders; P Dupont; J Schoonjans; O Feron; J-P Machiels
Journal:  Ann Oncol       Date:  2012-04-03       Impact factor: 32.976

3.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

Authors:  D F Bajorin; P M Dodd; M Mazumdar; M Fazzari; J A McCaffrey; H I Scher; H Herr; G Higgins; M G Boyle
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Authors:  Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

5.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

Authors:  C N Sternberg; P de Mulder; J H Schornagel; C Theodore; S D Fossa; A T van Oosterom; J A Witjes; M Spina; C J van Groeningen; B Duclos; J T Roberts; C de Balincourt; L Collette
Journal:  Eur J Cancer       Date:  2005-12-05       Impact factor: 9.162

6.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Authors:  Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

7.  Management of cancer in the older person: a practical approach.

Authors:  L Balducci; M Extermann
Journal:  Oncologist       Date:  2000

8.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

9.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Authors:  Guru Sonpavde; Gregory R Pond; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; David J Vaughn; Guenter Niegisch; Peter Albers; Nicholas D James; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Awais Khan; Nicholas J Vogelzang; Tomasz M Beer; Walter M Stadler; Peter H O'Donnell; Cora N Sternberg; Jonathan E Rosenberg; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2012-11-26       Impact factor: 20.096

10.  Phase II study of everolimus in metastatic urothelial cancer.

Authors:  Matthew I Milowsky; Gopa Iyer; Ashley M Regazzi; Hikmat Al-Ahmadie; Scott R Gerst; Irina Ostrovnaya; Lan L Gellert; Rana Kaplan; Ilana R Garcia-Grossman; Deepa Pendse; Arjun V Balar; Anne Marie Flaherty; Alisa Trout; David B Solit; Dean F Bajorin
Journal:  BJU Int       Date:  2013-04-03       Impact factor: 5.588
View more
  1 in total

1.  Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.

Authors:  Daiane Teixeira DE Oliveira; Andre Luiz Ventura Savio; Joao Paulo DE Castro Marcondes; Tatiane Martins Barros; Ludmila Correia Barbosa; Daisy Maria Favero Salvadori; Glenda Nicioli DA Silva
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.